Oculis Q3 Loss Widens to CHF 18.2M as Expenses Climb; Cash Runs Into 2H 2029
OCS is trading near its 52-week low of $7.11 (11% above the low) on elevated volume (2.1× avg).
Summary
Oculis posted a Q3 net loss of CHF 18.24 million, wider than the CHF 9.97 million loss reported for Q2, as operating expenses rose to CHF 23.65 million on higher headcount costs and non-recurring corporate initiatives. The company ended the quarter with $252 million in cash and equivalents and says that funds operations into the second half of 2029. Pipeline progress is the offset: patient randomization is complete in the Licaminlimab PREDICT-1 trial, with topline results expected around year-end 2026, and Privosegtor PIONEER-1 enrollment continues, with IND clearance for acute MS relapse trials anticipated in Q4 2026. The wider loss is a modest negative, but the runway and near-term readout are what matter for a company this size. The 6-K filed at 21:15 ET also raised the ATM ceiling from $100 million to $125 million, adding potential dilution overhang.
At the time of this announcement, OCS was trading at $7.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471M. The 52-week trading range was $7.11 to $34.48. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.